Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
Harvard Business School
Johnson and Johnson
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,780,987

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,780,987 protect, and when does it expire?

Patent 7,780,987 protects GLUMETZA and is included in one NDA.

This patent has twenty-six patent family members in fourteen countries.

Summary for Patent: 7,780,987
Title:Controlled release dosage forms
Abstract:The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55.degree. C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
Inventor(s): Zhou; Fang (Centreville, VA), Maes; Paul (Potomac, MD)
Assignee: Biovail Laboratories International SRL (St. Michael, BB)
Application Number:10/370,109
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,780,987
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 7,780,987

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Santarus Inc GLUMETZA metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021748-002 Jun 3, 2005 AB3 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,780,987

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 536173   Start Trial
Australia 2003211145   Start Trial
Australia 2003211146   Start Trial
Canada 2476201   Start Trial
Canada 2476496   Start Trial
Cyprus 1112517   Start Trial
Denmark 1476138   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Medtronic
Moodys
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.